Germany's 2026 Health Reform: Financial Stabilization Amid Sector Concerns

The German Bundestag has passed a significant health reform known as the "Beitragssatzstabilisierungsgesetz," aimed at stabilizing the financial situation of the statutory health insurance (GKV) system. The reform addresses the urgent need to contain rising health expenditures, which had surged to over 336 billion euros last year and are expected to grow further. Health Minister Nina Warken (CDU) emphasized the necessity of this reform to prevent a system collapse.

Key measures introduced include increased co-payments for prescription medications, rising from a minimum of 5 euros to between 7.50 and 15 euros, a reduction in subsidies for dental prosthetics from 60% to 50%, and the exclusion of homeopathic treatments from statutory health insurance coverage. The contribution assessment ceiling for high earners will be raised by 300 euros in 2027, and free insurance coverage for spouses and partners will face new limitations. Additionally, the reform permits partial sick leave for long-term illnesses.

Despite these efforts, the reforms have sparked sharp criticism, especially from states like Rheinland-Pfalz. Ministerpräsident Gordon Schnieder (CDU) recognized the reform's difficulty but accepted the need for stabilizing contribution rates. However, Health Minister Clemens Hoch (SPD) and the hospital association warned that the package complicates ongoing hospital reform efforts and may endanger psychotherapeutic care. The hospital association forecasts a potential loss of at least 250 million euros in 2027, risking around 3,000 full-time job losses. The Kassenärztliche Vereinigung and labor unions like Verdi have voiced strong concerns over the reform's impact on medical care and hospital viability.

Baden-Württemberg's Health Minister Oliver Hildenbrand criticized the federal approach as insufficient. He highlighted worsening financial instability in hospitals, with increased risks of insolvencies, and lamented the minimal concessions made regarding federal subsidies for uninsured services. While the reform brings a shift from dynamic price adjustments to fixed manufacturer discounts in pharmaceuticals to increase predictability, initial burdens will rise. Hildenbrand also deplored setbacks in mental health care provisions, describing changes in psychotherapy regulations as regressive.

In a broader context, Cora Loh from the Federal Association of German Industry stressed the industrial health economy's role in national resilience and security. She argued that viewing healthcare spending as a long-term investment is vital, warning that short-term cost-cutting in reforms jeopardizes future stability and innovation in sectors like pharmaceuticals, medical technology, biotech, and digital health solutions.

As the coalition government seeks to align health expenditure growth with income development, the health reform faces opposition's claims of undermining patients' rights and increasing out-of-pocket expenses. The Federal Constitutional Court has upheld the reform against emergency applications, so implementation proceeds amid ongoing sectoral and political debate.